Ten stocks ended 2025 on a powerful note, each posting gains of more than fourfold over the course of the year. One of the companies notably stood out for skyrocketing by more than 1,700 percent.
In this article, we spotlight last year’s 10 stars and look back at the key catalysts behind their jump.
Our list exclusively focused on stocks with a market capitalization of at least $2 billion.
The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels
10. Aris Mining Corp. (NYSEAmerican:ARMN)
Aris Mining Corp. saw its share prices soar by 363.71 percent in full-year 2025, with the overall rally primarily driven by its expansion program, coupled with gold prices’ surge to record highs.
The steepest rally was observed late in November ahead of the Federal Reserve’s expected rate cut in their last meeting for 2025, during which policymakers lowered benchmark rates by 25 basis points.
The Fed’s move sparked buying appetite in precious metals such as silver and gold, which propelled their prices to record highs, as well as in mining firms, over expectations that the rate cut, by weakening the US dollar, would bolster demand for the dollar-denominated gold and silver.
Additionally, sentiment was boosted by announcements earlier in December that it is now on track to hit 1 million ounces of gold production annually following the full acquisition of Colombian firm Soto Norte.
The latter was a joint venture firm between Aris Mining Corp. (NYSEAmerican:ARMN) and MDC Industry Holding Company LLC, with the former holding the controlling stake totaling 51 percent prior to the full takeover.
Aris Mining Corp. (NYSEAmerican:ARMN) said that the recent takeover would support the company’s focus on building a large and diversified gold business across Colombia and Guyana.
9. EchoStar Corporation (NASDAQ:SATS)
EchoStar surged by 374.67 percent in 2025, an impressive recovery from what could be a turbulent year that almost put the company into bankruptcy, thanks to a series of billion-dollar deals with technology giants that regained investor confidence.
It can be recalled that EchoStar Corporation (NASDAQ:SATS) in May this year announced that it intentionally did not settle $326 million of interest payments for one of its senior notes following the Federal Communications Commission’s (FCC) initiation of a review to probe into the former’s compliance obligations to provide 5G services in the US.
According to EchoStar Corporation (NASDAQ:SATS), the review froze its ability to make decisions on the interest payments.
President Donald Trump later intervened and directed the two parties to resolve their dispute.
Late in August, EchoStar Corporation (NASDAQ:SATS) said that it officially sold licenses amounting to $23 billion to AT&T as part of its efforts to resolve the dispute.
In separate transactions in September and November, the company also sold its remaining AWS-3 and AWS-4 licenses to Elon Musk-led SpaceX for a total of $19.6 billion, in exchange for a combination of cash and SpaceX shares. The transaction effectively made EchoStar Corporation (NASDAQ:SATS) one of the significant shareholders of SpaceX.
Lastly, the company’s surge to new records last month was boosted by news about SpaceX’s plan to list publicly in a bid to raise as much as $30 billion in fresh funds, a transaction that could bolster the company’s IPO valuation to $1.5 trillion.
8. Grail Inc. (NASDAQ:GRAL)
Grail Inc. soared by 379.5 percent in 2025, with the rally primarily boosted by a combination of bullish analyst ratings and strong confidence for its cancer early detection test kit.
Called Galleri, the tool is a single blood test designed to screen more than 50 types of cancer. In its Pathfinder 2 clinical study for the test kit, the company reported an overall positive predictive value of 61.6 percent, meaning that when Galleri flagged the test as positive, cancer was later confirmed in 61.6 percent of those cases.
Earlier this year, Grail Inc. (NASDAQ:GRAL) earned the backing of the Samsung group for the exclusive distribution of Galleri to South Korea and other key Asian markets, potentially Japan and Singapore.
In line with the collaboration, Samsung likewise acquired a $110 million stake in Grail Inc. (NASDAQ:GRAL), covering shares at a price of $70.05 apiece.
Meanwhile, several analysts have posted an upbeat coverage for Grail Inc. (NASDAQ:GRAL) and Galleri. Canaccord, for its part, issued a “buy” recommendation and a price target of $105 earlier, or 25 percent higher than its previous target of $85, amid the significant progress in the adoption and reimbursement for Galleri.
Morgan Stanley also raised its price target to $110 from $85 previously, while maintaining its “equal weight” rating for the stock.
Grail Inc. (NASDAQ:GRAL) said that it would seek the Food and Drug Administration’s (FDA) pre-market approval for the tool within the first quarter of 2026.
7. Planet Labs PBC (NYSE:PL)
Planet Labs soared by 388.12 percent in 2025, with the highest jump bolstered by its stellar earnings performance in the last reported quarter and a more upbeat outlook for the fiscal year 2026.
Following its earnings call early last month, Planet Labs PBC (NYSE:PL) saw its share prices shoot up by as much as 35 percent in just a day, fueled by its higher revenue outlook of $297 million to $301 million for the full fiscal year, versus $281 million to $289 million previously, alongside a 14 percent revenue beat for the third quarter of the year.
In the last reported quarter, Planet Labs PBC (NYSE:PL) said that revenues soared by 32 percent to $81.2 million from $61.3 million in the same period last year, exceeding its earlier target of $71 million to $74 million. Nine-month tally saw a climb of 20.8 percent to $220.9 million versus $182.8 million prior.
Net loss, however, nearly tripled to $59.18 million from $20 million year-on-year, bringing its nine-month net loss higher by 7.2 percent to $94.4 million from $88.04 million.
Following the results, Planet Labs PBC (NYSE:PL) received a buy recommendation from various analysts, including Needham, Cantor Fitzgerald, Citigroup, and Clear Street, among others.
6. TMC the metals company Inc. (NASDAQ:TMC)
TMC the metals company soared by 450.89 percent in 2025, thanks to a flurry of catalysts, including the surging demand for its mined metals, as well as the Trump administration’s confirmation that it would start to review its deep-sea mining intent this month.
TMC the metals company Inc. (NASDAQ:TMC) was notably trading just around the $1 level a year ago, until it announced in April its official intent with the US government to mine in the international seabed—a move that significantly propelled its share prices higher but also earned the ire of members of the International Seabed Authority (ISA).
According to the ISA, of which Canada is a member, TMC the metals company Inc. (NASDAQ:TMC) bypassed the agency for submitting its deep-sea mining intention with the US—a non-ISA member—while originally being a Canadian company.
For its part, the listed firm said that the submission was made through its US subsidiary.
Meanwhile, the US government last month confirmed that it would review the listed firm’s application through a series of public hearings beginning this January.
In other developments, TMC the metals company Inc. (NASDAQ:TMC), also benefited from the electric vehicle and energy boom, which has accelerated the buildout of more power infrastructures. This, in turn, drove stronger demand for battery and industrial metals such as copper, nickel, cobalt, and manganese, which are the key focus of its mining operations.
5. Terns Pharmaceuticals Inc. (NASDAQ:TERN)
Terns Pharmaceuticals climbed by 629.64 percent in 2025, primarily boosted by stellar results from the clinical trial of its therapy candidate for chronic myeloid leukemia (CML), which has the potential to become the best-in-class therapy versus other existing treatments.
At the 67th American Society of Hematology (ASH) Annual Meeting and Exposition early last month, Terns Pharmaceuticals Inc. (NASDAQ:TERN) said that its therapy candidate, TERN-701, recorded a 64 percent improvement in the conditions of 63 enrolled patients with CML after taking the pill for 24 weeks.
Additionally, it saw a 74 percent major molecular response rate at higher doses of 320 mg.
Of the total enrollees, 55 patients remained on treatment, with four dropping out due to disease progression.
Meanwhile, three stopped due to the physician and patient’s decision, while one stopped after experiencing adverse effects.
Following the results, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) successfully raised $747.5 million in fresh funds from the issuance of more than 18.68 million shares to the public. Part of the proceeds will be allocated for the development, manufacturing, preparation, and future commercial launch of TERN-701, while the balance will be used for working capital and other general corporate purposes.
4. Celcuity Inc. (NASDAQ:CELC)
Celcuity climbed by 661.96 percent in 2025, with the overall rally primarily fueled by strong results from the phase 3 clinical trial of its treatment candidate for breast cancer.
In an updated report which was presented to the 2025 San Antonio Breast Cancer Symposium early last month, Celcuity Inc. (NASDAQ:CELC) said that its treatment candidate, gedatolisib, in combination with palbociclib and fulvestrant, saw patients’ cancer stay under control for around 12.4 months, while those who took the gedatolisib and fulvestrant combination saw progression-free survival (PFS) for 10 months.
The results represented a significant improvement from only 1.9 months in PFS for those who took the fulvestrant alone.
Additional safety analyses were also performed, with mouth sore the only most common side effect observed.
“We are very excited that patients reported nearly two years of delay in definitive deterioration of their well-being. This provides meaningful evidence of how well patients tolerated the gedatolisib regimens. This safety-profile, combined with the 16.6 months of median PFS reported for patients from the U.S., Canada, Western Europe, and Asia Pacific who received the gedatolisib triplet, further highlights the differentiated profile of the gedatolisib regimens,” said Celcuity Inc. (NASDAQ:CELC) Chief Medical Officer Igor Gorbatchevsky.
3. Cidara Therapeutics Inc. (NASDAQ:CDTX)
Cidara Therapeutics climbed by 721.76 percent in 2025, primarily bolstered by its looming merger with Merck for $9.2 billion.
In an announcement last November, Cidara Therapeutics Inc. (NASDAQ:CDTX) said that it signed a definitive agreement with Merck, under which the latter’s subsidiary would acquire the former’s issued and outstanding shares at a price of $221.50 apiece. At that time, the acquisition price represented a 108 percent premium over Cidara Therapeutics Inc.’s (NASDAQ:CDTX) closing price of $105.99 on November 13, or prior to the announcement of the deal.
The acquisition followed Cidara Therapeutics, Inc. (NASDAQ:CDTX) receipt of a fast track designation from the Food and Drug Administration for its drug candidate, CD388, which aims to prevent influenza in individuals at higher risk of complications.
The CD388 is currently being evaluated in a Phase 3 study among 6,000 adult and adolescent participants in the US and the UK who are at higher risk of developing complications from influenza.
“This acquisition expands and complements our respiratory portfolio and pipeline. Influenza continues to pose a significant global health threat, causing widespread illness, morbidity and death each year especially in older adults and immunocompromised individuals, such as those with cancer and chronic diseases,” said Merck Research Laboratories President Dean Li.
“CD388 is a novel late-phase candidate with important strain-agnostic properties being evaluated for the prevention of symptomatic influenza in high-risk individuals.”
The merger is expected to be completed in the first quarter of 2026, subject to regulatory and shareholder approvals.
2. Almonty Industries Inc. (NASDAQ:ALM)
Almonty Industries saw its share prices jump by 840.13 percent in 2025, primarily bolstered by its aggressive expansion into tungsten production, in line with its goal to become one of the leading producers of the said metal.
Late last year, Almonty Industries Inc. (NASDAQ:ALM) announced a flurry of developments aimed to ramp up its tungsten production portfolio, including the acquisition and commercial operations of several mining sites in the US and in South Korea.
Last month, Almonty Industries Inc. (NASDAQ:ALM) announced the looming start of commercial operations at its mine site in South Korea following the successful delivery of the first truckload of ore to the Run-of-Mine pad at the Sangdong Tungsten Mine, marking the final step before the kickoff.
Almonty Industries Inc. (NASDAQ:ALM) acquired the Sangdong mine when the US halted its mining operations in 2015. Since then, it has been working on bringing the site back into production.
In November, meanwhile, Almonty Industries Inc. (NASDAQ:ALM) successfully acquired the Gentung Browns Lake Tungsten Project in Beaverhead County, Montana, and commenced drilling operations at its Panasqueira Mine in Portugal.
The Panasqueira Mine alone is being expanded into Level 4 operations, a 2.5 million euro operation to drill 14,000 meters with three rigs over a 12-month period.
1. ABIVAX Societe Anonyme (NASDAQ:ABVX)
Abivax skyrocketed by 1,742.28 percent in 2025, as investor sentiment was primarily bolstered by a series of upbeat analyst outlooks, strong clinical trial results, and its official inclusion in Nasdaq’s biotechnology index.
ABIVAX Societe Anonyme (NASDAQ:ABVX) officially joined the Nasdaq biotechnology index (NBI) on December 22, an index designed to track the performance of a set of biotechnology and pharmaceutical companies listed on Nasdaq.
Companies belonging to the index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria.
“Our inclusion in the Nasdaq Biotechnology Index marks a significant milestone for Abivax. It highlights the meaningful progress we’ve made as a company, particularly in advancing obefazimod through the successful Phase 3 ABTECT Induction trials for ulcerative colitis and reflects the increased visibility and perception of Abivax within the global biotechnology community,” said ABIVAX Societe Anonyme (NASDAQ:ABVX) Chief Finance Officer Didier Blondel.
Meanwhile, ABIVAX Societe Anonyme (NASDAQ:ABVX) also earned “buy” recommendations from a series of investment companies, namely Guggenheim Securities, Truist Financial, and Citizens, alongside price targets of $175, $140, and $131, respectively, reflecting upbeat analyst outlooks.
The coverage followed strong results from the phase 3 trial to test the efficacy of obefazimod in patients with moderate to severe ulcerative colitis, where enrolled patients who took 50 mg of obefazimod saw a significant improvement in their conditions and their colon lining, suggesting real disease healing.
While we acknowledge the potential of ABVX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABVX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
